Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study

Objective: The aim of the study was to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for the treatment of vaginal atrophy in postmenopausal women. Methods: This was a randomized, placebo-controlled trial of 60 postmenopausal women aged 40 to 70 years at the Menopause Clinic of CAISM UNICAMP. Women were randomized into three vaginal treatment groups: estrogen, testosterone, or placebo. The treatment was applied 3 times a week for 12 weeks. Hormonal laboratory values of follicle-stimulating hormone, luteinizing hormone, estradiol, estrone, androstenedione, total testosterone, free testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin were assessed at baseline and at 6 and 12 weeks. Metabolic laboratory values of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase were also assessed at baseline and at 6 and 12 weeks. Endometrial safety was assessed using ultrasonography at baseline and at 12 weeks. Results: After 12 weeks of treatment, there were no significant differences in hormonal or metabolic laboratory values among all three groups. Two participants in the estrogen group had increased serum estradiol after 12 weeks of treatment. No change in endometrial thickening was reported in all three groups. Conclusions: Twelve weeks of treatment with topical testosterone or estrogen in postmenopausal women with symptoms of vaginal atrophy demonstrated laboratory and endometrial safety when compared with placebo.

[1]  L. Esserman,et al.  Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial , 2017, JAMA oncology.

[2]  N. Panay,et al.  Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. , 2017, Fertility and sterility.

[3]  J. Pinkerton The 2017 hormone therapy position statement of The North American Menopause Society. , 2017, Menopause.

[4]  A. Pinto-Neto,et al.  Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial , 2016, Menopause.

[5]  F. Labrie,et al.  Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause , 2016, Menopause.

[6]  S. Davis,et al.  Testosterone in women--the clinical significance. , 2015, The lancet. Diabetes & endocrinology.

[7]  A. Pinto-Neto,et al.  Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. , 2014, The journal of sexual medicine.

[8]  M. Martens,et al.  Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society , 2013, Menopause.

[9]  A. Perrone,et al.  Androgen receptor expression in the human vagina under different physiological and treatment conditions , 2013, International Journal of Impotence Research.

[10]  B. Littenberg,et al.  Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. , 2011, The oncologist.

[11]  L. Derogatis,et al.  Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. , 2011, Fertility and sterility.

[12]  C. Stika Atrophic vaginitis , 2010, Dermatologic therapy.

[13]  P. Dubey,et al.  A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. , 2010, The journal of sexual medicine.

[14]  C. Labrie,et al.  Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy , 2009, Menopause.

[15]  C. Labrie,et al.  Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women , 2009, Menopause.

[16]  G. Braunstein,et al.  Testosterone for low libido in postmenopausal women not taking estrogen. , 2008, The New England journal of medicine.

[17]  I. Goldstein,et al.  Differential regulation of the expression of estrogen, progesterone, and androgen receptors by sex steroid hormones in the vagina: immunohistochemical studies. , 2006, The journal of sexual medicine.

[18]  C. Castelo-Branco,et al.  Management of post-menopausal vaginal atrophy and atrophic vaginitis. , 2005, Maturitas.

[19]  F. Labrie,et al.  Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  C. Castelo-Branco,et al.  Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. , 2005, Maturitas.

[21]  A. Lethaby,et al.  Local oestrogen for vaginal atrophy in postmenopausal women. , 2003, The Cochrane database of systematic reviews.

[22]  T. Bourne,et al.  Ultrasound in gynecology: endometrium , 1997, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  A. Haspels,et al.  The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. , 1980, Maturitas.